Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?

Checkpoint inhibition (CPI) has been a rare success story in the field of cancer immunotherapy. Knowledge gleaned from preclinical studies and patients that do not respond to these therapies suggest that the presence of tumor-infiltrating lymphocytes and establishment of immunostimulatory conditions...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamichhane, Purushottam, Amin, Neha P., Agarwal, Manuj, Lamichhane, Narottam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313567/
https://www.ncbi.nlm.nih.gov/pubmed/30360504
http://dx.doi.org/10.3390/medicines5040114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313567/
https://www.ncbi.nlm.nih.gov/pubmed/30360504
http://dx.doi.org/10.3390/medicines5040114

Ejemplares similares